Immunologic changes associated with allergen immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 2, 1998, Pages 157-164

  Durham, Stephen R ^a   Till, Stephen J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CD4 ANTIGEN; CD8 ANTIGEN; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; PROSTAGLANDIN D2;

ALLERGY; ANAPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; MAST CELL; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0031784380     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70079-X     Document Type: Article

References (48)

1. Frew AJ. Injection inimunotherapy. British Society for Allergy and Clinical Immunology Working Party. BrMed J 1993;307:919-23.
2. Mailing H, Weese B. Position paper of the European Academy of Allergy and Clinical Immunology. Allergy 1993;48(Suppl 14):9-35.
3. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985;76:2247-53.
4. Gomez E, Clague JE, Gatland D, Davies RJ. Effect of topical corticosteroids on seasonally induced increases in nasal mast cells. Br Med J Clin Res Ed 1988;296:1572-3.
5. Bentley AM, Jacobson MR, Cumberworth V, Barkans JR, Moqbel R, Schwartz LB, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992;89:877-83.
6. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immun otherapy. Clin Exp Allergy 1991;21:115-9.
7. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994;93:484-93.
8. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
9. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32.
10. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:470-80.
11. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;97:1356-65.
12. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472-82.
13. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70:261-71.
14. Mailing HJ, Skov PS, Permin H, Norn S, Weeke B. Basophil histamine release and humoral changes during immunotherapy. Dissociation between basophil-bound specific IgE, serum value, and cell sensitivity. Allergy 1982;37:187-90.
15. Djurup R, Mailing HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:459-68.
16. Carballido JM, Carballido Perrig N, Oberli Schrammli A, Heusser CH, Blaser K. Regulation of IgE and IgG4 responses by allergen specific T cell clones to bee venom phospholipase A2 in vitro. J Allergy Clin Immunol 1994;93:758-67.
17. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-204.
18. Yamashita N, Takeno M, Kaneko S, Mizushima Y, Sakane T. Therapeutic effects of preferential induction of mite-specific T helper 0 clones. Clin Exp Immunol 1997;109:332-41.
19. Visco V, Dolecek C, Denepoux S, Le Mao J, Guret C, Rousset F, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157:956-62.
20. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T cell clones specific for Phi p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007-15.
21. Aalberse RC, Van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993;48:559-69.
22. Barcy S, Wettendorff M, Leo O, Urbain J, Kruger M, Ceuppens JL, et al. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int Immunol 1995;7:179-89.
23. Djurup R, Osterballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984;39:433-41.
24. Muller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989;44:412-8.
25. Reisman RE. Should routine measurements of serum venom-specific IgG be a standard of practice in patients receiving venom immunotherapy? J Allergy Clin Immunol 1992;90:282-4.
26. Wierenga EA, Snoek M, de Groot C, Chretien I, Bos JD, Jansen HM, et al. Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients. J Immunol 1990;144:4651-6.
27. Renz H, Lack G, Saloga J, Schwinzer R, Bradley K, Loader J, et al. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. J Immunol 1994;152:351-60.
28. McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993;178:889-99.
29. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213-9.
30. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol 1987;79:591-8.
31. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
32. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
33. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828-38.
34. Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP, Joseph M, et al. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes. Immunology 1996;87:593-8.
35. Till S, Walker S, Dickason R, Huston D, O'Brien F, Lamb J, et al. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997;110:114-21.
36. Durham SR, Varney V, Gaga M, Frew AJ, Jacobsen M, Kay AB. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991;21:206-10.
37. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
38. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
39. O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol 1991;3:819-26.
40. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 1992;356:607-9.
41. O'Hehir RE, Lamb JR. Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins. Proc Natl Acad Sci USA 1990;87:8884-8.
42. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by PL-2 and PL-15 in vitro. J Clin Invest 1996;98:1676-83.
43. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995;182:1579-84.
44. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-9.
45. Lebecque S, Dolecek C, Laffer S, Visco V, Denepoux S, Pin JJ, et al. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997;99:374-84.
46. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40.
47. Fahy IV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
48. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.